Health Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcript
Health Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcript
HCAT - Health Catalyst, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$2.25
DETAILS
HIGH:
$3.00
LOW:
$1.75
MEDIAN:
$2.00
CONSENSUS:
$2.25
UPSIDE:
74.42%
Stock News
Health Catalyst Q1 Earnings Call Highlights
Health Catalyst NASDAQ: HCAT reported first-quarter 2026 results that topped its own expectations, while management outlined a broad restructuring plan aimed at simplifying the company's operating model, reducing costs and shifting the business further toward technology-led growth.
Health Catalyst (HCAT) Q1 Earnings and Revenues Surpass Estimates
Health Catalyst (HCAT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.01 per share a year ago.
Compared to Estimates, Health Catalyst (HCAT) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Health Catalyst (HCAT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Health Catalyst Reports First Quarter 2026 Results
SALT LAKE CITY, May 11, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended March 31, 2026. “We delivered solid first quarter results, with revenue and adjusted EBITDA exceeding expectations,” said Ben Albert, Chief Executive Officer of Health Catalyst.
Seeking Clues to Health Catalyst (HCAT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Health Catalyst (HCAT) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Health Catalyst to Announce First Quarter 2026 Operating Results and Host Conference Call on Monday, May 11, 2026
SALT LAKE CITY, May 01, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, will release its first quarter 2026 operating results on Monday, May 11, 2026, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.
Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors
SALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Steve Nelson, Executive Vice President and President of Aetna, a CVS Health company, has been appointed to its Board of Directors, effective May 1, 2026. Nelson's appointment follows the naming of Ben Albert as CEO and Justin Spencer as Chairman of the Board earlier this year, continuing a deliberate pattern of leadership moves designed to accelerate the company's transformation– executing on a single, coordinated strategy to help health systems address cost, clinical outcomes, and consumer experience as one imperative.
Health Catalyst (NASDAQ:HCAT) versus MDxHealth (NASDAQ:MDXH) Head to Head Comparison
MDxHealth (NASDAQ: MDXH - Get Free Report) and Health Catalyst (NASDAQ: HCAT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends. Volatility and Risk MDxHealth has a beta of
Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of “Hold” by Brokerages
Health Catalyst, Inc. (NASDAQ: HCAT - Get Free Report) has earned an average recommendation of "Hold" from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The
Health Catalyst (HCAT) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Health Catalyst (HCAT) Lags Q4 Earnings Estimates
Health Catalyst (HCAT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.04 per share a year ago.
Health Catalyst, Inc. (HCAT) Q4 2025 Earnings Call Transcript
Health Catalyst, Inc. (HCAT) Q4 2025 Earnings Call Transcript
Health Catalyst Reports Fourth Quarter and Year End 2025 Results
SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2025. “We closed 2025 with solid performance across our business, including total revenue of $311.1 million and Adjusted EBITDA of $41.4 million,” said Ben Albert, CEO of Health Catalyst “In 2026, we are focused on the future and on positioning Health Catalyst for long‑term success.
Health Catalyst (HCAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Health Catalyst (HCAT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Gear Up for Health Catalyst (HCAT) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Health Catalyst (HCAT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Health Catalyst to Announce Fourth Quarter and Year End 2025 Operating Results and Host Conference Call on Thursday, March 12, 2026
SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and year end 2025 operating results on Thursday, March 12, 2026, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.
Health Catalyst Appoints Ben Albert as Chief Executive Officer
Albert to Sharpen Focus on Improving Cost and Operational Efficiency, Clinical Quality, and Consumer Experience in Healthcare Health Catalyst Board to be Reduced to Five Directors Immediately Prior to the 2026 Annual Meeting SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Health Catalyst, Inc. (Nasdaq: HCAT) ("Health Catalyst" or the "Company"), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Ben Albert, the Company's President and Chief Operating Officer (COO), was appointed to serve as Chief Executive Officer (CEO) and as a member of Health Catalyst's Board of Directors ( "Board"), effective February 12, 2026. In connection with the appointment, Health Catalyst accelerated the timing of its previously announced succession plan for Dan Burton, who has stepped down as CEO and as a member of the Board.
Down 20.4% in 4 Weeks, Here's Why Health Catalyst (HCAT) Looks Ripe for a Turnaround
Health Catalyst (HCAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down 21.4% in 4 Weeks, Here's Why Health Catalyst (HCAT) Looks Ripe for a Turnaround
Health Catalyst (HCAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Price Targets
Health Catalyst price target lowered to $1.75 from $2 at Stephens
$1.75
(was $1.38)
Stephens
Health Catalyst Inc. (HCAT) PT Lowered to $3 at Cantor Fitzgerald; No Turnaround Yet
$3.00
(was $1.79)
Sarah James
·
Raymond James
Health Catalyst Inc. (HCAT) PT Lowered to $2 at Canaccord
$2.00
(was $1.79)
Richard Close
·
Canaccord Genuity
Health Catalyst price target lowered to $3 from $4 at Evercore ISI
$3.00
(was $2.90)
Evercore ISI
Health Catalyst price target lowered to $4 from $5 at KeyBanc
$4.00
(was $2.85)
KeyBanc
Health Catalyst price target lowered to $5 from $9 at Canaccord
$5.00
(was $3.65)
Summit Redstone Partners
Health Catalyst price target lowered to $5 from $9 at Canaccord
$5.00
(was $3.65)
Richard Close
·
Canaccord Genuity
Health Catalyst price target lowered to $5 from $7 at KeyBanc
$5.00
(was $3.75)
Scott Schoenhaus
·
KeyBanc
Health Catalyst price target lowered to $5 from $7 at Stephens
$5.00
(was $4.43)
Stephens
Health Catalyst price target lowered to $7 from $9 at RBC Capital
$7.00
(was $6.98)
Sean Dodge
·
RBC Capital
Canaccord Genuity Reiterates Buy Rating on Health Catalyst Inc. (HCAT)
$11.00
(was $7.29)
Richard Close
·
Canaccord Genuity
Health Catalyst Inc. (HCAT) PT Lowered to $11 at Piper Sandler
$11.00
(was $7.19)
Jessica Tassan
·
Piper Sandler
Health Catalyst Inc. (HCAT) PT Lowered to $7 at Stephens
$7.00
(was $5.48)
Jeff Garro
·
Stephens
Health Catalyst Inc. (HCAT) PT Lowered to $14 at Piper Sandler
$14.00
(was $6.70)
Jessica Tassan
·
Piper Sandler
Guggenheim Upgrades Health Catalyst Inc. (HCAT) to Buy
$14.00
(was $9.94)
Jack Wallace
·
Guggenheim
Health Catalyst price target lowered to $21 from $38 at Piper Sandler
$21.00
(was $12.95)
Jessica Tassan
·
Piper Sandler
Health Catalyst (HCAT) Stock: $35 Price Target And Outperform Rating
$35.00
(was $27.54)
Sean Dodge
·
RBC Capital
Analysts Offer Insights on Technology Companies: Salesforce (NYSE: CRM), Health Catalyst (NASDAQ: HCAT) and Cloudflare (NYSE: NET)
$48.00
(was $27.54)
Elizabeth Anderson CFA
·
Evercore ISI
Health Catalyst initiated with a Buy at Goldman Sachs
$48.00
(was $30.14)
Cindy Motz CFA
·
Goldman Sachs
Health Catalyst price target raised to $60 from $55 at Truist
$60.00
(was $54.25)
Sandy Draper
·
Guggenheim